Biotechnology
All Devices Successfully Detected Colon Entry in Patients with Active Ulcerative Colitis Excerpt from the Press Release: SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced topline results from its recently completed study PM-602: A Scintigraphic Study to Evaluate the Localization and Delivery…
Read More
CRISPR/Cas system for bacteria that are not E. coli or Streptococcus pyogenes Customized gene editing technology for unique modified-bacteriophages To validate efficacy of SARS-CoV-2 mimotopes loaded PHAGERUS® platform Excerpt from the Press Release: BOSTON and SEOUL, South Korea, Aug. 9, 2022 /PRNewswire/ — iNtRON Biotechnology (“iNtRON”, www.intodeworld.com) announced today that iNtRON has developed its unique CRISPR/Cas system customized for the genetic modification of certain bacteria…
Read More
Company Creates “Younger T Cells” for Fighting Cancer Using its NR2F6 Technology Excerpt from the Press Release: SAN DIEGO, Aug. 11, 2022 /PRNewswire/ — Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) announced today the filing with the United States Patent and Trademark Office of a provisional US patent application covering the Company’s novel approach for…
Read More
Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–InterVenn® Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced the start of enrollment in its prospective cohort study for early detection of colorectal cancer and adenomas. This confirmatory Noninvasive Identification of Colorectal Cancer and Adenomas in Early Stages– better known as…
Read More Topline Pivotal trial results expected 1H2023 Excerpt from the Press Release: WAYNE, Pa. and ROCKVILLE, Md., Aug. 02, 2022 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX), announced the first patient has been dosed in the pivotal LADDER trial (A Phase 3, Randomized, Double-blind, Two-period, Crossover, Withdrawal Study to Assess the Efficacy and Safety of…
Read More
Study evaluating the safety and efficacy of gemlapodect (NOE-105) in adults with Childhood Onset Fluency Disorder (also known as stuttering) Top-line data expected in Q4 2023 Excerpt from the Press Release: BASEL, Switzerland and BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) — Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications, today…
Read More
– Phase 3 MANTRA trial completed enrollment five months ahead of previous guidance – – MANTRA topline data anticipated in 1H 2023 – – Management to host 2Q 2022 Earnings Call today at 5:00 PM Eastern Time – Excerpt from the Press Release: NEWARK, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) — Rain Therapeutics Inc. (NasdaqGS:…
Read More
– 200mg and 400mg Once-Daily Doses Achieved Strong Exposure Multiples Over EC90 and Were Generally Safe and Well-Tolerated – Plan to Initiate Phase 2 Study in 4Q 2022 Excerpt from the Press Release: WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver…
Read More
Excerpt from the Press Release: ATHENS, Ga. and LOS GATOS, Calif., July 21, 2022 /PRNewswire/ — Blue Lake Biotechnology, Inc., a clinical-stage biotechnology company developing vaccines using a proprietary transformational parainfluenza virus 5 (PIV5)-based vector, today announced the enrollment of the first participant in a Phase 1 clinical trial of their intranasal BLB-201 vaccine for RSV (respiratory syncytial virus)…
Read More
In a first, a patient in New Zealand has undergone gene-editing to lower their cholesterol. It could be the beginning of new era in disease prevention. Excerpt from the Press Release: A volunteer in New Zealand has become the first person to undergo DNA editing in order to lower their blood cholesterol, a step that…
Read More